IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients
Authors:
- Fernanda Manente MilanezFMFernanda Manente Milanez
- Carla G. S. SaadCSCarla G. S. Saad
- Vilma T. VianaVVVilma T. Viana
- Júlio C. B. MoraesJMJúlio C. B. Moraes
- Grégory Vinícius PéricoGPGrégory Vinícius Périco
- Percival Degrava Sampaio-BarrosPSPercival Degrava Sampaio-Barros
- Célio R. GoncalvesCGCélio R. Goncalves
- Eloísa BonfáEBEloísa Bonfá
Open Access
- 24 February 2016
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 18 (1) , 52
Abstract
Advances in pathophysiology and treatment of ankylosing spondylitis (AS) was recently demonstrated. However, the effect of anti-TNF in the newly described inflammatory pathways involved pathogenesis of this disease remains to be determined. The aim of our study was, therefore, to investigate long-term influence of anti-TNF drugs in IL-23/IL-17 axis of AS patients and their possible correlation with treatment, clinical, laboratory and radiographic parameters. Eighty-six AS anti-TNF naïve patients, 47 referred for anti-TNF therapy (active-AS; BASDAI ≥ 4) and 39 with BASDAI < 4 (control-AS) were included. The active group was evaluated at baseline, 12-months and 24-months after TNF blockade and compared at baseline to control-AS group and to 47 healthy age- and gender-matched controls. Plasma levels of IL-17A, IL-22, IL-23 and PGE2 were measured. Non-steroidal anti-inflammatory drugs (NSAIDs) intake were recorded every 6 months. Radiographic severity and progression was assessed by mSASSS at baseline and 24 months after therapy. At baseline, active-AS group presented higher IL-23 and PGE2 levels compared to control-AS group (p < 0.001 and p = 0.008) and to healthy controls (p < 0.001 and p = 0.02). After 24-months of TNF blockade, IL-23 and PGE2 remained elevated with higher levels compared with the healthy group (p < 0.001 and p = 0.03) in spite of significant improvements in all clinical/inflammatory parameters (p < 0.001). Further analysis of 27 anti-TNF-treated patients who achieved a good response (ASDAS-CRP < 2.1,with a drop ≥ 1.1) at 24-months revealed that IL-23 plasma levels remained higher than healthy controls (p < 0.001) and higher than control-AS group with similar disease activity (ASDAS-CRP < 2.1, p = 0.01). In active-AS group (n = 47), there was a strong correlation between IL-23 and IL-17A at baseline, 12-months and 24-months after anti-TNF therapy (p ≤ 0.001). This study provides novel data demonstrating that the IL-23/IL-17 axis is not influenced by TNF blockade in AS patients despite clinical and inflammation improvements and NSAID intake.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP (#2009/51897-5)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (#301411/2009-3)
- Research Grant Frederico Foundation
This publication has 50 references indexed in Scilit:
- JARID1A, JMY, and PTGER4 Polymorphisms Are Related to Ankylosing Spondylitis in Chinese Han Patients: A Case-Control StudyPLOS ONE, 2013
- Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein responseArthritis & Rheumatism, 2011
- Th17 Cells Expressing KIR3DL2+ and Responsive to HLA-B27 Homodimers Are Increased in Ankylosing SpondylitisThe Journal of Immunology, 2011
- Prostaglandins in bone: bad cop, good cop?Trends in Endocrinology & Metabolism, 2010
- Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 yearsArthritis Research & Therapy, 2009
- The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritisAnnals of the Rheumatic Diseases, 2009
- The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivoNature Immunology, 2009
- Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variantsNature Genetics, 2007
- Prostaglandin E2 receptors in bone formationInternational Orthopaedics, 2007
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984